[A17-37] Dolutegravir (HIV infection) - Addendum to commission A17-11
Last updated 21.09.2017
Project no.:
A17-37
Commission:
Commission awarded on 10.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
HIV infection in children with antiretroviral pretreatment or in treatment-naive children
Result of dossier assessment:
Added benefit still not proven: data from studies in adults not transferable to children
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-11 | Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-09-21 A G-BA decision was published.